Abstract LB-459: An essay concerning the molecular prediction of disease outcome in melanoma patients

• Published in: Cancer research (Chicago, Ill.) Ill.), 2012-04, Vol.72 (8_Supplement), p.LB-459-LB-459
• Main Authors: Gschaider, Melanie, Neumann, Friederike, Peters, Bettina, Lenz, Florian, Cibena, Micheal, Goiser, Malgorzata, Wolf, Ingrid, Wenzel, Jörg, Mauch, Cornelia, Schreiner, Wolfgang, Wagner, Stephan N.
• Format: Article
• Language: English
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/1538-7445.AM2012-LB-459

Melanoma is the most lethal form of skin cancer. Current prognostic clinical and histopathological parameters are insufficient to accurately predict the outcome of individual patients. Several studies have claimed gene expression signatures to predict survival or metastasis of primary melanoma patients. However, the reproducibility among these studies is disappointingly low and led to the development of guidelines on statistical analysis and reporting of gene expression data for cancer outcome. We carefully followed these guidelines when we used gene expression data from primary human melanoma samples to identify gene signatures predictive for disease outcome. The class comparison dataset was established using microarray data from non-metastatic and metastatic primary melanoma samples. The top 50 differentially expressed genes were identified by Significance Analysis of Microarrays and used in an independent gene expression data set of primary melanomas for prediction. Multivariate Cox regression analysis determined the classifier revealing the best predictive value. This classifier comprised the Duffy blood group chemokine receptor and the ribosomal protein S27-like and defined the cutoff positions for favorable and detrimental disease outcome, respectively. We report this classifier as an essay to provide molecular information supplementary to standard morphological prognostic factors. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-459. doi:1538-7445.AM2012-LB-459